WO2014136062A2 - Procédé pour la préparation de déférasirox - Google Patents

Procédé pour la préparation de déférasirox Download PDF

Info

Publication number
WO2014136062A2
WO2014136062A2 PCT/IB2014/059456 IB2014059456W WO2014136062A2 WO 2014136062 A2 WO2014136062 A2 WO 2014136062A2 IB 2014059456 W IB2014059456 W IB 2014059456W WO 2014136062 A2 WO2014136062 A2 WO 2014136062A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
deferasirox
hydroxyphenyl
oxazin
solvent
Prior art date
Application number
PCT/IB2014/059456
Other languages
English (en)
Other versions
WO2014136062A3 (fr
Inventor
Kothakonda Kiran KUMAR
Reddy Gearu DAMODAR
Venkata Srinivas Pullela
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Priority to ES14760971.3T priority Critical patent/ES2650118T3/es
Priority to JP2015560831A priority patent/JP6312718B2/ja
Priority to KR1020157027451A priority patent/KR102282372B1/ko
Priority to RU2015139499A priority patent/RU2659034C2/ru
Priority to DK14760971.3T priority patent/DK2964659T3/da
Priority to NO14760971A priority patent/NO2964659T3/no
Priority to US14/772,728 priority patent/US9593086B2/en
Priority to AU2014224252A priority patent/AU2014224252B2/en
Priority to EP14760971.3A priority patent/EP2964659B1/fr
Priority to CA2903712A priority patent/CA2903712C/fr
Priority to PL14760971T priority patent/PL2964659T3/pl
Publication of WO2014136062A2 publication Critical patent/WO2014136062A2/fr
Publication of WO2014136062A3 publication Critical patent/WO2014136062A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • the present disclosure discloses a robust process for the preparation of Deferasirox crystalline polymorphic form-I with superior quality.
  • Deferasirox is prepared via novel metal salt of the corresponding intermediate and deferasirox metal salt, which enables ease of operations and ensures better quality of the product.
  • Deferasirox (1) is an iron-chelator, which reduces iron overload in patients receiving long- term blood transfusions for conditions such as beta- thalassemia and other chronic anemia. It binds selectively with Fe 3+ ions in a 2: 1 ratio. Deferasirox is approved by FDA and marketed as Exjade®. Chemically deferasirox is 4-[3,5-Bis (2-hydroxyphenyl)-lH-l,2,4-triazol-lyl]- benzoic acid, having molecular formula C21H15N3O4, and the molecular weight 373.4.
  • US 6,465,504 Bl discloses substituted 3,5-diphenyl-l,2,4-triazoles and their use as pharmaceutical metal chelators in which salicyloyl chloride (Fromula-2) is reacted with salicylamide (Formula-3) at 170 °C to obtain 2-(2-hydroxyphenyl)benze[e][l,3]oxazin-4-one (Formula-4) as slightly yellow crystals having melting point 206-208 °C, which is then reacted with 4-hydrazinobenzoic acid (Formula-5) in ethanol under reflux conditions to obtain 4-[3,5-Bis (2-hydroxyphenyl)-lH-l,2,4-triazol-lyl]-benzoic acid (Deferasirox) as colorless crystals having melting point 264-265 °C.
  • deferasirox (1) was obtained as crystalline polymorphic form-I.
  • the obtained material does not meet the quality parameters such as chromatographic purity, residue on ignition, and appearance as per the ICH guidelines.
  • a need for a more robust purification process of this crude deferasirox is inevitable to meet the quality parameters of the final API.
  • the condensation of salicyloyl chloride with salicylamide was conducted at 170 °C, which is highly challenging and hazardous at commercial scales.
  • This reaction at this combustible temperature also generates by-products such as uncyclised derivative; 2-hydroxy-N-(2- hydroxybenzoyl) benzamide compound (bis-salicylamide) of formula-6, which is difficult to remove from desired product.
  • 2-hydroxy-N-(2- hydroxybenzoyl) benzamide compound bis-salicylamide
  • the above said impurity is formed more than 10%, in the scale up reactions the formation of this impurity is formed about >20%.
  • controlling the formation of this bis-salicylamide to minimum possible levels is essential.
  • Crystalline polymorphic form-I of deferasirox is disclosed in IPCOM000146862D, characterized by PXRD having 2 ⁇ values at about 13.2, 14.1, and 16.6 ⁇ 0.2 degrees.
  • the characteristic 2 ⁇ values of Form-I is further elaborated as 6.6, 10.0, 10.6, 20.3, 23.1, 25.7, 26.2 ⁇ 0.2 degrees.
  • WO 2008/065123 discloses use and the process of novel polymorphs designated as Form- A, B, C, D and Sb.
  • WO 2008/094617 reports the polymorphic forms of deferasirox designated as Form-II, Form-Ill, Form-IV and their conversion to most stable polymorph Form-I.
  • An Indian Patent application 1924/CHE/2008 reports novel solvates of deferasirox and their conversion to deferasirox.
  • the present disclosure relates to a process for preparing crystalline form of deferasirox having purity of at least 99%, said process comprising acts of: a) reacting salicyloyl chloride of formula 2 with salicylamide of formula 3 in presence of a catalyst to obtain 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one of formula 4 having less than 1% of uncyclized impurity, b) reacting salicyloyl chloride of formula 2 with salicylamide of formula 3 in presence of a catalyst and a metal base to obtain metal salt of 2-(2- Hydroxyphenyl)benz[e]oxazin-4-one of formula 4 having less than 1% of uncyclized impurity, c) reacting the 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one of step (a), or the metal salt of 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one of step (b), with
  • Figure 1 shows the PXRD of 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one Sodium (Sodium salt of Formula-4).
  • Figure 2 shows the PXRD of Deferasirox Form-1. DETAILED DESCRIPTION OF THE DISCLOSURE
  • the present disclosure relates to the process of preparation of deferasirox crystalline polymorph Form-I, which can be implemented safely in commercial scales. Surprisingly, the present disclosure addresses both process engineering aspects as well as quality aspects together.
  • the current disclosure further refers to the reaction at reduced temperatures, controlled at formation of impurities, clarification filtration to remove the in-organic waste, and purification of the crude deferasirox to remove unwanted impurities, and color.
  • the present disclosure relates to a process for preparing crystalline form of deferasirox having purity of at least 99%, said process comprising acts of: a.
  • the catalyst is a phase transfer catalyst.
  • the phase transfer catalyst is a quaternary ammonium halide, selected from a group comprising tetra alkyl ammonium halide and benzyl tri alkyl ammonium halide or a combination thereof.
  • the tetra alkyl ammonium halide is selected from a group comprising tetra butyl ammonium bromide, tetra ethyl ammonium bromide, tetra butyl ammonium chloride and tetra butyl ammonium iodide or any combination thereof; and wherein the benzyl tri alkyl ammonium halide is benzyl tri alkyl ammonium bromide.
  • the catalyst is at an amount ranging from about is 0.001 equivalents to about 2 equivalents.
  • the metal base is selected from a group comprising alkali metal base and alkaline earth metal base or a combination thereof.
  • the metal is Lithium, Sodium, Potassium, Magnesium and Calcium or any combination thereof.
  • the alkali metal base or the alkaline earth metal base is selected from a group comprising Lithium Hydroxide, Sodium hydroxide, Sodium methoxide, Potassium hydroxide and Potassium tertiary butoxide, or any combination thereof.
  • the uncyclized impurity is 2-hydroxy-N- (2-hydroxybenzoyl) benzamide (bis-salicylamide) of formula 6.
  • the reaction of step (a), i.e., reacting salicyloyl chloride of formula 2 with salicylamide of formula 3 in presence of a catalyst to obtain 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one of formula 4 having less than 1% of uncyclized impurity comprises acts of: a. adding salicylamide and the catalyst to the salicyloyl chloride in a solvent to obtain a solid mass;
  • the reaction of step (b), i.e., reacting salicyloyl chloride of formula 2 with salicylamide of formula 3 in presence of a catalyst and a metal base to obtain metal salt of 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one of formula 4 having less than 1% of uncyclized impurity comprises acts of: a. adding salicylamide and the catalyst to the salicyloyl chloride in a solvent to obtain a solid mass;
  • step (a) and (b) of the main process as described above are carried at temperature ranging from about 35°C to about 170°C.
  • step (c) i.e., reacting the 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one of step (a), or the metal salt of 2-(2- Hydroxyphenyl)benz[e]oxazin-4-one of step (b), with 4-hydrozenobenzoic acid of formula 5 to obtain semi-pure form of deferasirox, comprises acts of: a.
  • the reaction of step (c) of the main process comprises acts of: a. adding 4-hydrozenobenzoic acid to the metal salt of 2-(2- Hydroxyphenyl)benz[e]oxazin-4-one of formula 4, and refluxing the reaction mixture for a time period ranging from about 1 hour to about 3 hours followed by cooling to a temperature of less that about 40°C to obtain a precipitate; and
  • the acidification is carried out by acids selected from a group comprising Hydrochloric acid and Hydrobromic acid or a combination thereof.
  • the purification of step (d), i.e., purifying the semi-pure form of deferasirox in a solvent to obtain the crystalline form of deferasirox having purity of at least 99% comprises acts of: a. dissolving the semi-pure form of deferasirox in a solvent at reflux temperature to obtain a reaction mass;
  • step (d) of the main process comprises acts of: a. dissolving the semi-pure form of deferasirox in a solvent at reflux temperature to obtain a reaction mass;
  • the solvent is selected from a group comprising dichloromethane, dichloroethane, chloroform, methanol, ethanol, isopropanol, toluene, xylene, tetrahydrofuran, dimethyl formamaide, ethyl acetate, isopropyl acetate, diethyl ether, diisopropyl ether, methyl tertiary butyl ether, petroleum ether, hexanes, heptanes and water or any combination thereof.
  • the crystalline form of deferasirox is a polymorphic form Form-I of deferasirox, having the 2 ⁇ values 6.6, 10.0, 10.6, 20.3, 23.1, 25.7 and 26.2 ⁇ 0.2 degrees.
  • the present disclosure relates to a 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one compound of formula-4 or a metal salt thereof, having less than 1% of uncyclized impurity
  • the uncyclized impurity is 2-hydroxy-N-(2- hydroxybenzoyl) benzamide (bis-salicylamide) of formula 6.
  • the metal salt is a sodium salt of 2-(2- Hy droxyphenyl)benz [e] oxazin-4-one .
  • the sodium salt of 2-(2- Hydroxyphenyl)benz[e]oxazin-4-one is characterized by PXRD, having 2o values at about: 6.02, 6.90, 7.18, 10.80, 11.29, 12.02, 12.73, 13.30, 13.98, 14.49, 16.29, 17.13, 18.06, 18.99, 19.42, 19.97, 20.97, 21.63, 22.50, 22.93, 23.48, 24.26, 24.89, 26.38, 26.75, 27.47, 27.95, 28.42, 29.22, 29.80, 31.57, 34.88 and 40.06 ⁇ 0.2 degrees.
  • salicyloyl chloride (Formula-2) is generated from salicylic acid by reacting with acid chloride selected from a group comprising thionyl chloride, oxaloyl choride, phosphoryl chloride and phosphorous pentachloride or any mixture thereof, in a suitable solvent selected from a group comprising toluene, xylene, tetrahydrofuran and dimethylformamide or any mixture thereof.
  • the resulting salicyloyl chloride (Formula-2) is reacted with salicylamide (Formula-3) in presence of a reaction stabilizer, which is a phase transfer catalyst, to obtain 2-(2-hydroxyphenyl)benze[e][l,3]oxazin-4-one (Formula-4) with maximum conversion and having minimal by-product (Formula-6) in the reaction mixture crude.
  • the phase transfer catalyst is a quaternary ammonium halide, selected from a group comprising tetra alkyl ammonium halide and benzyl tri alkyl ammonium halide or a combination thereof.
  • the tetra alkyl ammonium halide is selected from a group comprising tetra butyl ammonium bromide, tetra ethyl ammonium bromide, tetra butyl ammonium chloride and tetra butyl ammonium iodide or any combination thereof.
  • the benzyl tri alkyl ammonium halide is benzyl tri alkyl ammonium bromide.
  • the phase transfer catalyst is used in catalytic to stoichiometric ratios, which stabilizes the reaction and controls the formation of bis- salicylamide.
  • the reaction is carried in a suitable solvent selected from a group comprising toluene, xylenes, THF, DMF and dichloromethane, or any mixture thereof, or optionally the reaction is carried out in neat.
  • the temperature of the reaction is maintained between 35-170 °C, more preferably between 65-130°C, and most preferably between 75-120 °C.
  • the use of solvent in this reaction allows washing of the cake to remove the unwanted impurities.
  • the recovery of the product of Formula-4 is much higher than the reported procedure.
  • the reaction mixture wherein the product of Formula-4 is obtained, is allowed to precipitate, and the precipitate is isolated as a solid with better quality having the by-product of Formula-6 in a concentration of less than about ⁇ 1%, more preferably ⁇ 0.5%, most preferably ⁇ 0.2%.
  • intermediate of Formula-4 is also extracted in solution form into organic solvents selected from a group comprising dichloromethane, dichloroethane and chloroform or any mixture thereof, and then carried to the next reaction.
  • intermediate compound having Formula-4 or sodium salt of the intermediate Formula-4 is prepared in a single operation by following: to salicylic acid, salicylamide and TBAB, in dimethyl formamide / toluene mixture and thionyl chloride is added and reacted till the completion of the reaction. After the completion of the reaction, volatile compounds are distilled off from the reaction mixture. Isopropanol is added, and the solid is separated by filtration. In case of sodium salt: after the completion of the reaction, sodium methoxide is added to the reaction mixture. The resultant sodium salt is precipitated and isolated by filtration.
  • the reaction mixture is dissolved in dichloromethane and sodium methoxide was added to form the corresponding sodium salt of the intermediate 2-(2-hydroxyphenyl) benze[e][l,3]oxazin- 4-one (Formula-4).
  • the salt so formed is allowed to precipitate and the precipitate is further isolated by filtration.
  • the salt is found to be pure and crystalline in nature.
  • Polymorph of the sodium salt of Formula-4 is characterized by PXRD designated as Form-X, having 2o values at about: 6.02, 6.90, 7.18, 10.80, 11.29, 12.02, 12.73, 13.30, 13.98, 14.49, 16.29, 17.13, 18.06, 18.99, 19.42, 19.97, 20.97, 21.63, 22.50, 22.93, 23.48, 24.26, 24.89, 26.38, 26.75, 27.47, 27.95, 28.42, 29.22, 29.80, 31.57, 34.88, 40.06 ⁇ 0.2.
  • 2-(2- hydroxyphenyl)benze[e][l,3]oxazin-4-one (Formula-4) or the corresponding sodium salt is reacted with 4-hydrazinobenzoic acid (Formula-5) in suitable solvent such as a C1-C4 alcohol selected from a group comprising methanol, ethanol, isopropanol, dimethylformamide, dichloromethane and water or any mixture thereof. More preferably, when C1-C4 alcohols or aqueous alcohols are used as solvents the purity and the conversions are better. Most preferably, water is used as single solvent for this reaction.
  • suitable solvent such as a C1-C4 alcohol selected from a group comprising methanol, ethanol, isopropanol, dimethylformamide, dichloromethane and water or any mixture thereof. More preferably, when C1-C4 alcohols or aqueous alcohols are used as solvents the purity and the conversions are better. Most preferably, water is used as single solvent for this reaction
  • the volumes of solvents used are 2-70 volumes, more preferably 10-45 volumes and most preferably 20-35 volumes.
  • the temperature of the reaction is maintained between 35-120 °C, more preferably between 50-110°C and most preferably between 65-105 °C.
  • the mass is cooled to less than about 70 °C, more preferably to less than 45 °C and most preferably to less than 30 °C, for complete precipitation. Thereafter the precipitated solid is isolated.
  • the isolated wet cake is optionally washed, and sucked dry.
  • the material isolated is semi-pure with respect to the chromatographic purity having about >99% purity and the appearance is greyish pale yellow.
  • the reaction between sodium salt of 2-(2- hydroxyphenyl)benze[e][l,3]oxazin-4-one and 4-hydrazinobenzoic acid results in the sodium salt of the deferasirox.
  • This is then suspended in organic solvent such as isopropanol and acidified with aqueous acid such as hydrochloric acid.
  • aqueous acid such as hydrochloric acid.
  • the resulting mixture is allowed to precipitate, and the resultant deferasirox is isolated as crystalline polymorphic form-1.
  • the semi-pure deferasirox (optionally dried cake) is purified to obtain the substantially pure deferasirox colorless crystals with > 99.2% chromatographic purity.
  • the solvents used for purification are C1-C4 alcohols selected from a group comprising methanol, ethanol and isopropanol, lower chain esters selected from a group comprising ethyl acetate and isopropyl acetate, lower chain ethers selected from a group comprising diethyl ether, diisopropyl ether and methyl tertiary butyl ether, hydrocarbons selected from a group comprising petroleum ether, hexanes and heptanes, or any mixture thereof.
  • the volumes of solvents used are between 5-75 volumes, more preferably between 10-50 volumes and most preferably between 15-45 volumes.
  • the temperature of the purification process is between 20-120 °C, more preferably between 40-90 °C and most preferably between 50-85 °C.
  • charcoal treatment is given to remove the color impurities, and filtered through the celite to remove the insoluble particles.
  • Addition of the solvent to the semi-pure deferasirox is done in portion wise, or on continuous basis, or in one shot at appropriate temperature. Clarified deferasirox solution is allowed to cool for precipitation, and further stirred for complete precipitation. The resulted solid is isolated by filtration, or centrifugation.
  • the wet-cake is washed and sucked dry under vacuum. The isolated material is further dried under vacuum at appropriate temperature till it meets the residual solvents limits as per ICH.
  • the final deferasirox is found to be substantially pure having the chromatographic purity >99.2%, more preferably > 99.5% and most preferably >99.7%.
  • the PXRD of the isolated deferasirox is having peaks pertaining to Form-I at about 2 ⁇ values 6.6, 10.0, 10.6, 20.3, 23.1, 25.7, 26.2 ⁇ 0.2 degrees.
  • Salicylic chloride has been prepared from Salicylic acid.
  • salicyloyl Chloride salicylamide is added and the reaction is heated > 170 °C and then maintained for about 0.5h.
  • the reaction mass is cooled to 70 °C, ethanol is added, and then cooled to room temperature.
  • the suspension is filtered, the wet cake is washed with ethanol and the the material is dried. (Recovery: 80%, purity: 74%, Impurity Formula-6: 16.9%).
  • Oxaloyl chloride (1 L) is added slowly to salicyclic acid (1.2 Kg) in tetrahydro furan (10 L) / DMF (100 mL) and heated to about 50-75 °C along with stirring. The stirring is continued for about 1 h and the volatile components are distilled off to obtain the syrup of salicyloyl chloride (Formula-2) (1.3 Kg).
  • Example-3 Typical Preparation of 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one (Formula- 4) using phase transfer catalyst:
  • Example-6 Preparation of 4-[3,5-Bis(2-hydroxyphenyl)-[l,2,4]triazol-l-yl]benzoic acid (Deferasirox):
  • Example-7 Preparation of 4-[3,5-Bis(2-hydroxyphenyl)-[l,2,4]triazol-l-yl]benzoic acid (Deferasirox) from 2-(2-Hydroxyphenyl)benz[e]oxazin-4-one Sodium:
  • Example-11 Purification of 4-[3,5-Bis(2-hydroxyphenyl)-[l,2,4]triazol-l-yl]benzoic acid (Deferasirox):

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention porte sur le procédé industriellement viable pour la préparation de déférasirox et de son polymorphe. Le procédé selon l'invention comprend la préparation de déférasirox par l'intermédiaire d'un sel métallique de l'intermédiaire correspondant et de sel métallique de déférasirox.
PCT/IB2014/059456 2013-03-06 2014-03-05 Procédé pour la préparation de déférasirox WO2014136062A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES14760971.3T ES2650118T3 (es) 2013-03-06 2014-03-05 Proceso para la preparación de deferasirox
JP2015560831A JP6312718B2 (ja) 2013-03-06 2014-03-05 デフェラシロクスを調製するための方法
KR1020157027451A KR102282372B1 (ko) 2013-03-06 2014-03-05 데페라시록스의 제조 방법
RU2015139499A RU2659034C2 (ru) 2013-03-06 2014-03-05 Способ получения деферазирокса
DK14760971.3T DK2964659T3 (da) 2013-03-06 2014-03-05 Fremgangsmåde til fremstilling af deferasirox
NO14760971A NO2964659T3 (fr) 2013-03-06 2014-03-05
US14/772,728 US9593086B2 (en) 2013-03-06 2014-03-05 Process for the preparation of deferasirox
AU2014224252A AU2014224252B2 (en) 2013-03-06 2014-03-05 Process for the preparation of Deferasirox
EP14760971.3A EP2964659B1 (fr) 2013-03-06 2014-03-05 Procédé pour la préparation de déférasirox
CA2903712A CA2903712C (fr) 2013-03-06 2014-03-05 Procede pour la preparation de deferasirox
PL14760971T PL2964659T3 (pl) 2013-03-06 2014-03-05 Sposób wytwarzania deferazyroksu

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN975/CHE/2013 2013-03-06
INCH09752013 2013-03-06

Publications (2)

Publication Number Publication Date
WO2014136062A2 true WO2014136062A2 (fr) 2014-09-12
WO2014136062A3 WO2014136062A3 (fr) 2015-02-19

Family

ID=51492065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/059456 WO2014136062A2 (fr) 2013-03-06 2014-03-05 Procédé pour la préparation de déférasirox

Country Status (1)

Country Link
WO (1) WO2014136062A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105541746A (zh) * 2016-02-01 2016-05-04 太仓市茜泾化工有限公司 一种2-（4-甲氧基苯基）-4H-苯并[e][1,3]噁嗪-4-酮的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772503B2 (en) * 2009-12-07 2014-07-08 Mapi Pharma Ltd. Processes for the preparation of deferasirox, and deferasirox polymorphs
US8907083B2 (en) * 2010-08-25 2014-12-09 Ramamohan Rao Davuluri Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-IH-I, 2, 4-triazolTI-yl] benzoic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2964659A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105541746A (zh) * 2016-02-01 2016-05-04 太仓市茜泾化工有限公司 一种2-（4-甲氧基苯基）-4H-苯并[e][1,3]噁嗪-4-酮的制备方法

Also Published As

Publication number Publication date
WO2014136062A3 (fr) 2015-02-19

Similar Documents

Publication Publication Date Title
US20100076196A1 (en) Process for the preparation of iloperidone
JP2005350474A (ja) シロスタゾールの製造方法
US6515128B2 (en) Processes for preparing cilostazol
AU2014224252B2 (en) Process for the preparation of Deferasirox
EP2643306B1 (fr) Procédé pour la préparation de déférasirox
WO2014136062A2 (fr) Procédé pour la préparation de déférasirox
US20100029939A1 (en) Preparation of ketone amides
CA1082198A (fr) Procede de preparation d'un compose therapeutique actif
US8163924B2 (en) Process for preparing a leukotriene antagonist and an intermediate thereof
FI77860C (fi) Foerfarande foer framstaellning av 5,11-dihydro-6h-pyrido /2,3-b/ /1,4/ benzodiazepin-6-oner.
EP0454871B1 (fr) Cetone alpha, beta-insaturee et derive de cetoxime
WO2008020453A2 (fr) Procédé pour la préparation d'un nouveau polymorphe cristallin de l'aripiprazole
JP4258590B2 (ja) ハロゲン置換キノリン誘導体の製造方法
CA2150948A1 (fr) Methode de preparation d'alpha-aryl-gamma-butyrolactones
TW200538455A (en) Improved process for the preparation of (ethoxymethyl)-tropane derivatives
US5703233A (en) Quinilone disulfide as intermediates
KR0119280B1 (ko) 신규한 5-메틸퀴놀론계 항생제의 중간체 및 이의 제조방법
KR890002639B1 (ko) 퀴놀린 유도체의 제조 방법
JPH0234943B2 (fr)
JPH0551365A (ja) ４−オキソキノリン−３−カルボン酸類の製造方法
KR19980047902A (ko) 퀴놀론계 항생제 중간체인 베타-케토 에스테르 유도체의 제조방법
JPH0236164A (ja) ２‐ニトロ‐５‐（置換アリールオキシ）ベンゾヒドロキシム酸誘導体の製造法

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2903712

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14772728

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015560831

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014224252

Country of ref document: AU

Date of ref document: 20140305

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014760971

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014760971

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157027451

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015139499

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14760971

Country of ref document: EP

Kind code of ref document: A2